Emotion and Motivation in Patients With Psychosis

Influence of Emotion and Motivation on Behaviour and Neural Activity in Patients With Psychosis

Anhedonia and avolition reflect emotional and motivational disorders, respectively. However, if these disorders play a major role in the symptomatology of schizophrenia, their mechanisms remain poorly understood, and existing treatments are inefficient on these symptoms. The literature suggests that the impairment does not concern emotion or motivation per se, but rather their influence on cognition. This project aims at using recent advances in the fundamental domain to better understand the cognitive and neuronal mechanisms of the patients' alterations, and especially how emotion and motivation influence cognition in schizophrenia.

Study Overview

• Status: Recruiting
• Conditions: Schizophrenia
• Intervention / Treatment: Other: Electroencephalogram; Behavioral: Cognitive tasks; Behavioral: subjective evaluation scales

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Anne GIERSCH; Phone Number: 03 88 11 64 71; Email: giersch@unistra.fr

Study Locations

• France
  • Strasbourg, France, 67091
    • Recruiting
    • Unité INSERM 1114
    • Sub-Investigator: Pierre VIDAILHET, MD, PhD
    • Sub-Investigator: Fabrice BERNA, MD, PhD
    • Contact: Anne GIERSCH, MD, PhD; Phone Number: 03 88 11 64 71; Email: giersch@unistra.fr
    • Principal Investigator: Anne GIERSCH, MD, PhD
    • Sub-Investigator: Laurence LALANNE, MD, PhD
    • Sub-Investigator: Sébastien WEIBEL, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• diagnostic and Statistical Manual of Mental Disorders criteria for schizophrenia

Exclusion Criteria:

• addiction problem
• invalidating visual sensory problems
• neurological history
• for the healthy volunteers: psychiatric history

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Patients with schizophrenia	Other: Electroencephalogram; electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli; Behavioral: Cognitive tasks; - clinical scales and subjective assessments of emotional and motivational stimuli; Behavioral: subjective evaluation scales; - clinical scales and subjective assessments of emotional and motivational stimuli
Sham Comparator: Healthy volunteers	Other: Electroencephalogram; electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli; Behavioral: Cognitive tasks; - clinical scales and subjective assessments of emotional and motivational stimuli; Behavioral: subjective evaluation scales; - clinical scales and subjective assessments of emotional and motivational stimuli

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the amplitude of the CNV (Contingent Negative Variation) as a function of the primer displayed on the screen	Before each cognitive trial a primer will be displayed, which will be either neutral or convey emotion or motivation. The investigators will check whether this primer affects the subjects preparation by measuring the CNV, which is an evoked potential recorded with electroencephalography, and indexing preparatory effort.	During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the amplitude of the LPP (Late Positive Potential) as a function of the primer displayed on the screen	The investigators will check whether primers affect the subjects attention by measuring the LPP, which is an evoked potential recorded with electroencephalography, and indexing sustained attention.	During EEG sessions, at experimental session 1 (Day 0) and experimental session 2 (up to Day 120)

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France
• Collaborators: Institut National de la Santé Et de la Recherche Médicale, France

Study record dates

Study Major Dates

• Study Start (Actual): February 2, 2017
• Primary Completion (Estimated): June 1, 2025
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: May 23, 2016
• First Submitted That Met QC Criteria: July 28, 2016
• First Posted (Estimated): August 2, 2016

Study Record Updates

• Last Update Posted (Actual): August 21, 2023
• Last Update Submitted That Met QC Criteria: August 18, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: cognition; Emotion; schizophrenia; motivation
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: 6152

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No